Intuitive Surgical (NASDAQ:ISRG) Given "Buy" Rating at BTIG Research

Key Points

• Intuitive Surgical's stock has been given a "buy" rating by BTIG Research with a price target of $571.00, suggesting a potential upside of 27.67% from its current price.
• The company's recent quarterly earnings showed a profit of $2.19 per share, surpassing analysts' estimates and reflecting a 21.4% increase in revenue year-over-year.
• Thirteen analysts rate Intuitive Surgical as a "Buy," while there is a consensus average price target of $595.95, indicating positive sentiment towards the stock.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at BTIG Research in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $571.00 price target on the medical equipment provider's stock. BTIG Research's target price indicates a potential upside of 27.67% from the company's current price.

ISRG has been the subject of several other research reports. UBS Group boosted their price objective on shares of Intuitive Surgical from $547.00 to $585.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. Erste Group Bank restated a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Truist Financial boosted their target price on Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a research report on Wednesday, July 23rd. Wells Fargo & Company boosted their price objective on Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a report on Wednesday, July 23rd. Finally, Wall Street Zen lowered Intuitive Surgical from a "buy" rating to a "hold" rating in a report on Friday, September 26th. Thirteen analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Intuitive Surgical has a consensus rating of "Moderate Buy" and an average price target of $595.95.

Intuitive Surgical Stock Up 1.8%

ISRG opened at $447.23 on Wednesday. Intuitive Surgical has a twelve month low of $425.00 and a twelve month high of $616.00. The company has a market capitalization of $160.32 billion, a price-to-earnings ratio of 62.38, a PEG ratio of 4.60 and a beta of 1.61. The firm has a 50-day moving average price of $466.61 and a 200-day moving average price of $500.97.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. The business had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. Intuitive Surgical's revenue was up 21.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.78 EPS. On average, sell-side analysts expect that Intuitive Surgical will post 6.43 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Amy L. Ladd sold 335 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $440.69, for a total value of $147,631.15. Following the completion of the sale, the director owned 739 shares of the company's stock, valued at approximately $325,669.91. This represents a 31.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Myriam Curet sold 4,500 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $492.48, for a total value of $2,216,160.00. Following the sale, the executive vice president owned 353 shares of the company's stock, valued at $173,845.44. This represents a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 45,224 shares of company stock valued at $21,716,492. Corporate insiders own 0.70% of the company's stock.

Institutional Investors Weigh In On Intuitive Surgical

Several institutional investors have recently added to or reduced their stakes in ISRG. Chilton Capital Management LLC boosted its holdings in shares of Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after purchasing an additional 43 shares during the period. Tobam lifted its holdings in Intuitive Surgical by 666.7% in the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider's stock worth $25,000 after buying an additional 40 shares during the period. Elite Financial Inc. purchased a new stake in Intuitive Surgical in the 1st quarter worth approximately $26,000. Kilter Group LLC purchased a new stake in Intuitive Surgical in the 2nd quarter worth approximately $27,000. Finally, LFA Lugano Financial Advisors SA purchased a new stake in Intuitive Surgical in the 1st quarter worth approximately $30,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.